EnsoData acquired a sleep testing diagnostic technology from Resonea aimed at reducing the cost of systematically addressing sleep apnea across large patient populations, the company announced today.

According to a release, the company is now adding acoustic flow and microphone data channels to enable a new way to pre-screen patients for sleep apnea with an FDA-cleared mobile application and extend the diagnostic capabilities of home sleep testing.

“We are very excited to bring both acoustic flow and microphone data to the sleep community to expand the clinical data available for the health systems and providers utilizing PPG-based sleep testing,” EnsoData CEO Justin Mortara said in a statement. “This is another step toward simplifying access to sleep care, helping to get more patients with sleep disorders diagnosed and ultimately connected with therapy.”

The availability of the new capabilities is expected sometime this year.

Resonea is located in Scottsdale, Ariz.